Traders Purchase High Volume of Call Options on Agilent Technologies (A)

Agilent Technologies Inc (NYSE:A) was the recipient of some unusual options trading on Tuesday. Stock investors bought 4,240 call options on the company. This represents an increase of approximately 902% compared to the average volume of 423 call options.

Shares of NYSE:A opened at $67.20 on Thursday. Agilent Technologies has a twelve month low of $60.42 and a twelve month high of $75.00. The company has a market cap of $22.49 billion, a P/E ratio of 28.47, a price-to-earnings-growth ratio of 2.42 and a beta of 1.32. The company has a quick ratio of 3.00, a current ratio of 3.62 and a debt-to-equity ratio of 0.39.

Agilent Technologies (NYSE:A) last announced its earnings results on Tuesday, August 14th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.04. Agilent Technologies had a return on equity of 18.61% and a net margin of 6.20%. The firm had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter in the prior year, the company earned $0.59 EPS. The firm’s revenue for the quarter was up 8.0% compared to the same quarter last year. On average, equities research analysts forecast that Agilent Technologies will post 2.71 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 24th. Investors of record on Tuesday, October 2nd will be paid a dividend of $0.149 per share. The ex-dividend date of this dividend is Monday, October 1st. This represents a $0.60 annualized dividend and a yield of 0.89%. Agilent Technologies’s payout ratio is 25.42%.

In other news, Director Heidi Fields sold 5,482 shares of the company’s stock in a transaction dated Tuesday, September 11th. The stock was sold at an average price of $67.73, for a total transaction of $371,295.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul N. Clark sold 2,876 shares of the company’s stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $68.60, for a total value of $197,293.60. The disclosure for this sale can be found here.

A number of large investors have recently made changes to their positions in A. SRS Capital Advisors Inc. raised its holdings in Agilent Technologies by 75.9% in the 2nd quarter. SRS Capital Advisors Inc. now owns 1,791 shares of the medical research company’s stock valued at $110,000 after acquiring an additional 773 shares in the last quarter. Bray Capital Advisors raised its holdings in Agilent Technologies by 12,000.0% in the 2nd quarter. Bray Capital Advisors now owns 3,025 shares of the medical research company’s stock valued at $187,000 after acquiring an additional 3,000 shares in the last quarter. Retirement Capital Strategies acquired a new position in Agilent Technologies in the 3rd quarter valued at approximately $222,000. ELM Advisors LLC acquired a new position in Agilent Technologies in the 3rd quarter valued at approximately $228,000. Finally, Pwmco LLC acquired a new position in Agilent Technologies in the 2nd quarter valued at approximately $226,000.

Several research firms have recently issued reports on A. Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $74.00 price target for the company in a research note on Tuesday, August 7th. Deutsche Bank upped their price target on Agilent Technologies from $77.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, August 15th. Goldman Sachs Group upgraded Agilent Technologies from a “buy” rating to a “conviction-buy” rating in a research note on Monday, September 17th. ValuEngine upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Thursday, September 13th. Finally, Morgan Stanley increased their target price on Agilent Technologies from $83.00 to $84.00 and gave the company an “overweight” rating in a research note on Wednesday, August 15th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $77.44.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.

See Also: Earnings Per Share

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply